Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

  • Yvette Drew*
  • , Jae-Weon Kim
  • , Richard T Penson
  • , David M O'Malley
  • , Christine Parkinson
  • , Patricia Roxburgh
  • , Ruth Plummer
  • , Seock-Ah Im
  • , Martina Imbimbo
  • , Michelle Ferguson
  • , Ora Rosengarten
  • , Neeltje Steeghs
  • , Min Hwan Kim
  • , Einav Gal-Yam
  • , Daliah Tsoref
  • , Jae-Hoon Kim
  • , Benoit You
  • , Maja de Jonge
  • , Roy Lalisang
  • , Eelke Gort
    • Sara Bastian, Kassondra Meyer, Laura Feeney, Nigel Baker, Mei-Lin Ah-See, Susan M Domchek, Susana Banerjee
*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

INIS

Pharmacology, Toxicology and Pharmaceutical Science